Flavia V. Castelino, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Scleroderma, Systemic | 20 | 2023 | 323 | 5.860 |
Why?
|
Lung Diseases, Interstitial | 9 | 2021 | 808 | 2.130 |
Why?
|
Lysophospholipids | 3 | 2016 | 331 | 0.960 |
Why?
|
Scleroderma, Diffuse | 4 | 2023 | 17 | 0.800 |
Why?
|
Hypertension, Pulmonary | 2 | 2023 | 1537 | 0.700 |
Why?
|
Phosphoric Diester Hydrolases | 2 | 2016 | 197 | 0.660 |
Why?
|
Skin | 6 | 2023 | 4364 | 0.610 |
Why?
|
Benzoates | 2 | 2016 | 217 | 0.540 |
Why?
|
Receptors, Lysophosphatidic Acid | 2 | 2012 | 76 | 0.500 |
Why?
|
Coronary Aneurysm | 1 | 2016 | 237 | 0.460 |
Why?
|
Pulmonary Fibrosis | 2 | 2016 | 530 | 0.420 |
Why?
|
Scleroderma, Localized | 2 | 2023 | 79 | 0.410 |
Why?
|
Connective Tissue Diseases | 2 | 2013 | 264 | 0.400 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2016 | 546 | 0.390 |
Why?
|
Acro-Osteolysis | 2 | 2020 | 3 | 0.390 |
Why?
|
Fibroblasts | 3 | 2016 | 4161 | 0.380 |
Why?
|
Eicosanoids | 1 | 2012 | 279 | 0.380 |
Why?
|
Autoimmunity | 1 | 2018 | 1349 | 0.370 |
Why?
|
Hypertension, Malignant | 1 | 2019 | 19 | 0.350 |
Why?
|
Chest Pain | 1 | 2016 | 1114 | 0.340 |
Why?
|
Disease Management | 1 | 2018 | 2459 | 0.310 |
Why?
|
Paresthesia | 1 | 2008 | 161 | 0.300 |
Why?
|
Interleukin-6 | 1 | 2016 | 3200 | 0.290 |
Why?
|
Bleomycin | 3 | 2016 | 512 | 0.250 |
Why?
|
Gastrointestinal Diseases | 2 | 2023 | 1170 | 0.250 |
Why?
|
Vital Capacity | 3 | 2021 | 925 | 0.240 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1889 | 0.230 |
Why?
|
Fibrosis | 3 | 2016 | 2029 | 0.220 |
Why?
|
Registries | 6 | 2023 | 8089 | 0.220 |
Why?
|
Calcinosis | 2 | 2022 | 1499 | 0.210 |
Why?
|
Tobacco Use Cessation | 1 | 2023 | 95 | 0.210 |
Why?
|
Rheumatology | 2 | 2018 | 576 | 0.190 |
Why?
|
Headache | 1 | 2008 | 1226 | 0.190 |
Why?
|
Cytokines | 2 | 2016 | 7322 | 0.190 |
Why?
|
Lung | 3 | 2016 | 9856 | 0.170 |
Why?
|
Idiopathic Pulmonary Fibrosis | 2 | 2013 | 451 | 0.150 |
Why?
|
Interinstitutional Relations | 1 | 2018 | 241 | 0.140 |
Why?
|
Respiratory Function Tests | 2 | 2019 | 1616 | 0.140 |
Why?
|
Acute Kidney Injury | 1 | 2019 | 1972 | 0.140 |
Why?
|
Gastroesophageal Reflux | 1 | 2023 | 782 | 0.140 |
Why?
|
Severity of Illness Index | 6 | 2023 | 15540 | 0.140 |
Why?
|
Phosphodiesterase Inhibitors | 1 | 2016 | 215 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2022 | 592 | 0.130 |
Why?
|
Kidney | 2 | 2019 | 7186 | 0.120 |
Why?
|
Adaptive Immunity | 1 | 2019 | 713 | 0.120 |
Why?
|
Humans | 30 | 2023 | 744343 | 0.120 |
Why?
|
Immune System Diseases | 1 | 2016 | 262 | 0.110 |
Why?
|
Research Personnel | 1 | 2018 | 573 | 0.110 |
Why?
|
Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.110 |
Why?
|
Mentors | 1 | 2018 | 631 | 0.110 |
Why?
|
Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
Signal Transduction | 1 | 2014 | 23403 | 0.100 |
Why?
|
Hand | 3 | 2022 | 884 | 0.100 |
Why?
|
Biomedical Research | 2 | 2018 | 3309 | 0.100 |
Why?
|
Lung Injury | 1 | 2016 | 436 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2021 | 13989 | 0.100 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18029 | 0.090 |
Why?
|
Immunohistochemistry | 2 | 2016 | 11366 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3870 | 0.090 |
Why?
|
Mycophenolic Acid | 2 | 2021 | 343 | 0.080 |
Why?
|
Labetalol | 1 | 2008 | 30 | 0.080 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2016 | 1821 | 0.080 |
Why?
|
Sural Nerve | 1 | 2008 | 106 | 0.080 |
Why?
|
Amlodipine | 1 | 2008 | 83 | 0.080 |
Why?
|
Anemia, Hemolytic | 1 | 2019 | 168 | 0.080 |
Why?
|
Immunosuppressive Agents | 1 | 2021 | 4149 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2019 | 2958 | 0.080 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3505 | 0.070 |
Why?
|
Guanine | 1 | 2008 | 274 | 0.070 |
Why?
|
Adult | 10 | 2022 | 214055 | 0.070 |
Why?
|
Delphi Technique | 1 | 2019 | 778 | 0.070 |
Why?
|
Proteinuria | 1 | 2019 | 658 | 0.070 |
Why?
|
Animals | 6 | 2016 | 168757 | 0.070 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 2291 | 0.070 |
Why?
|
Phenotype | 1 | 2023 | 16365 | 0.070 |
Why?
|
Drug Discovery | 1 | 2013 | 1058 | 0.070 |
Why?
|
Autoantibodies | 1 | 2013 | 2035 | 0.060 |
Why?
|
Morbidity | 1 | 2010 | 1769 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5102 | 0.060 |
Why?
|
Consensus | 1 | 2013 | 2959 | 0.060 |
Why?
|
Coronary Angiography | 1 | 2016 | 4577 | 0.060 |
Why?
|
Vasculitis | 1 | 2008 | 519 | 0.060 |
Why?
|
Female | 11 | 2022 | 380194 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2016 | 4560 | 0.060 |
Why?
|
Substance Abuse, Intravenous | 1 | 2008 | 525 | 0.060 |
Why?
|
Prednisone | 1 | 2008 | 1574 | 0.060 |
Why?
|
Hepatitis B | 1 | 2008 | 695 | 0.050 |
Why?
|
Electrocardiography | 1 | 2016 | 6442 | 0.050 |
Why?
|
Biopsy | 2 | 2019 | 6756 | 0.050 |
Why?
|
Middle Aged | 8 | 2022 | 213383 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 9959 | 0.050 |
Why?
|
Disease Progression | 1 | 2018 | 13284 | 0.050 |
Why?
|
Chemokine CCL8 | 1 | 2021 | 18 | 0.050 |
Why?
|
Chemokine CCL19 | 1 | 2021 | 35 | 0.050 |
Why?
|
Sequence Analysis, RNA | 2 | 2019 | 2012 | 0.050 |
Why?
|
Mass Screening | 1 | 2017 | 5255 | 0.050 |
Why?
|
Chemokine CXCL9 | 1 | 2021 | 132 | 0.050 |
Why?
|
Male | 10 | 2022 | 350118 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2008 | 1381 | 0.050 |
Why?
|
Self Report | 2 | 2023 | 3558 | 0.050 |
Why?
|
beta 2-Microglobulin | 1 | 2021 | 315 | 0.050 |
Why?
|
Chemokine CXCL10 | 1 | 2021 | 304 | 0.040 |
Why?
|
Antibodies, Antineutrophil Cytoplasmic | 1 | 2022 | 288 | 0.040 |
Why?
|
Raynaud Disease | 1 | 2019 | 74 | 0.040 |
Why?
|
United States | 3 | 2021 | 69872 | 0.040 |
Why?
|
Mice | 3 | 2016 | 81183 | 0.040 |
Why?
|
Patient Care Team | 1 | 2010 | 2531 | 0.040 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 357 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2016 | 21746 | 0.040 |
Why?
|
Drug Therapy, Combination | 1 | 2008 | 6489 | 0.040 |
Why?
|
Prognosis | 2 | 2021 | 29063 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15076 | 0.040 |
Why?
|
Physicians | 1 | 2015 | 4567 | 0.040 |
Why?
|
Uncertainty | 1 | 2022 | 734 | 0.040 |
Why?
|
Submandibular Gland | 1 | 2016 | 86 | 0.030 |
Why?
|
Mice, Knockout | 1 | 2011 | 14557 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 176 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2021 | 2242 | 0.030 |
Why?
|
Nasal Septum | 1 | 2016 | 127 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12261 | 0.030 |
Why?
|
Methotrexate | 1 | 2021 | 1727 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2017 | 20129 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2016 | 793 | 0.030 |
Why?
|
Treatment Outcome | 3 | 2023 | 63114 | 0.030 |
Why?
|
Blood Pressure | 1 | 2019 | 8554 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12959 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2016 | 692 | 0.030 |
Why?
|
Program Development | 1 | 2018 | 1316 | 0.020 |
Why?
|
Ischemia | 1 | 2020 | 1907 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2018 | 1504 | 0.020 |
Why?
|
Aged | 4 | 2021 | 163280 | 0.020 |
Why?
|
Regression Analysis | 1 | 2019 | 6459 | 0.020 |
Why?
|
Qualitative Research | 1 | 2018 | 2682 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 764 | 0.020 |
Why?
|
Hypertension | 1 | 2019 | 8480 | 0.020 |
Why?
|
Mental Health | 1 | 2022 | 3019 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 3597 | 0.020 |
Why?
|
International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
Gene Expression | 1 | 2019 | 7799 | 0.020 |
Why?
|
Prospective Studies | 2 | 2021 | 53288 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2019 | 12245 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2019 | 12026 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2010 | 57776 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2759 | 0.020 |
Why?
|
Curriculum | 1 | 2018 | 3605 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2016 | 3474 | 0.020 |
Why?
|
Databases, Factual | 1 | 2019 | 7729 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2022 | 19905 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9438 | 0.010 |
Why?
|
Risk Factors | 1 | 2010 | 72290 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7766 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12804 | 0.010 |
Why?
|
Societies, Medical | 1 | 2013 | 3743 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 40561 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 21827 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56430 | 0.010 |
Why?
|
Adolescent | 1 | 2019 | 85781 | 0.010 |
Why?
|